Developers argued that culture-based microbial sterility testing remains a major bottleneck for personalized cell therapy manufacturing because USP sterility testing can take 14 days. They highlighted that fresh CAR T products often must be released before full results arrive, using interim culture results around 48 hours under exceptional protocols. The commentary frames the core operational constraint: incubation windows are regulatory rather than process-optimization driven, limiting manufacturing makers’ ability to shorten vein-to-vein timelines. The piece proposes parallel analysis pathway alternatives designed to improve speed without losing regulatory rigor. For manufacturing teams, the practical impact is a clearer justification for why faster sterility approaches are strategically central to decentralized CAR T scale-up.